Building on our 50 year heritage in respiratory research, we remain relentless in our pursuit to improve the outcomes for patients with asthma and COPD.
Alongside inhaled approaches, where the focus is on helping patients achieve good control of their symptoms, we are developing the next generation of treatments – novel biologics and medicines that target the underlying causes of disease. Beyond asthma and COPD, we are actively exploring treatments for other respiratory diseases, such as idiopathic pulmonary fibrosis and acute lung injury.
In the future, improvements in the treatment of respiratory diseases will come not only from new medicines but also from innovations in patient care, including adherence and treatment personalisation.”
View our full product development pipeline.
Explore more features
Severe asthma: when nature’s natural defences work against us
Inhaler innovation: more than a simple piece of plastic
At first glance, an inhaler may look like a simple piece of plastic. But inside, a complicated process and an internal ‘engine’ operate seamlessly...
An 'everyday' world first in clinical trials
The way we design and carry out clinical trials is being turned on its head by the advent of the Salford Lung Study (SLS).
Why is it that some people, particularly children, grow out of their asthma? That’s a question our scientists are asking as part of our research to better understand the disease.
COPD is more than a lung disease
Ruth Tal-Singer works in respiratory research and development. Here she shares her unique perspective on how the future of COPD treatment is changing.
Scientists or detectives? Seeking new clues in COPD
More on areas of research
How we research new medicines
Our research focuses on science related to the immune system and human genetics, while leveraging advanced technologies including functional genomics, artificial intelligence and machine learning – all of this is driven by the multiplier effect of Science x Technology x Culture.
How we research new vaccines
We invest in scientific and technical excellence to develop and launch new innovative vaccines that meet the needs of patients and payers.